Galvani Bioelectronics

Galvani Bioelectronics is a Stevenage, United Kingdom-based[5] bioelectronics R&D company.

Galvani Bioelectronics
TypeSubsidiary
IndustryBioelectronics
FoundedNovember 2016[1]
Founders
[2]
Headquarters
Stevenage[3]
,
United Kingdom[1]
Key people
Kristoffer Famm (President)[4]
ParentGlaxoSmithKline (55% equity interest)[3]
Websitegalvani.bio

History

It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][2] The partnership to form the company was announced on 1 August 2016.[3]

Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner.[3] The initial agreed upon investment between the two companies is up to £540 million over a period of seven years[3][6] and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions."[7] Additionally, both companies agreed to contribute their existing intellectual property rights.

References
  1. "Galvani Bioelectronics Website". Galvani Bioelectronics. Retrieved 24 December 2016.
  2. "Galvani Bioelectronics". Verily Life Sciences website. Retrieved 24 December 2016.
  3. Temperton, James (1 August 2016). "GSK and Google just created a £540m bioelectronic health firm". Wired. Retrieved 24 December 2016.
  4. "Kristoffer Famm Ph.D. - Galvani Bioelectronics". Galvani Bioelectronics. Retrieved 25 December 2016.
  5. Kollewe, Julia (2017-08-28). "Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline". the Guardian. Retrieved 2018-08-03.
  6. "Bioelectric Medicine Market Focusing Long-Term Professional Industry and Making New Commitments to the Sustainable Future". Worldanalytics24.com. 23 January 2019. Retrieved 2019-01-31.
  7. "Galvani Bioelectronics". FierceBiotech. Retrieved 2020-07-13.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.